Auray-Blais C - Search Results

1

Globotriaosylsphingosine (Lyso-Gb₃) as a biomarker for cardiac variant (N215S) Fabry disease.

Alharbi FJ, Baig S, Auray-Blais C, Boutin M, Ward DG, Wheeldon N, Steed R, Dawson C, Hughes D, Geberhiwot T. Alharbi FJ, et al. J Inherit Metab Dis. 2018 Mar;41(2):239-247. doi: 10.1007/s10545-017-0127-2. Epub 2018 Jan 2. J Inherit Metab Dis. 2018. PMID: 29294190

2

Development of a filter paper method potentially applicable to mass and high-risk urinary screenings for Fabry disease.

Auray-Blais C, Cyr D, Mills K, Giguère R, Drouin R. Auray-Blais C, et al. J Inherit Metab Dis. 2007 Feb;30(1):106. doi: 10.1007/s10545-006-0444-3. Epub 2006 Dec 14. J Inherit Metab Dis. 2007. PMID: 17171433

3

Quebec neonatal mass urinary screening programme: from micromolecules to macromolecules.

Auray-Blais C, Cyr D, Drouin R. Auray-Blais C, et al. J Inherit Metab Dis. 2007 Aug;30(4):515-21. doi: 10.1007/s10545-007-0607-x. Epub 2007 Jun 14. J Inherit Metab Dis. 2007. PMID: 17570073

4

Urinary globotriaosylceramide excretion correlates with the genotype in children and adults with Fabry disease.

Auray-Blais C, Cyr D, Ntwari A, West ML, Cox-Brinkman J, Bichet DG, Germain DP, Laframboise R, Melançon SB, Stockley T, Clarke JT, Drouin R. Auray-Blais C, et al. Mol Genet Metab. 2008 Mar;93(3):331-40. doi: 10.1016/j.ymgme.2007.10.001. Epub 2007 Nov 26. Mol Genet Metab. 2008. PMID: 18023222

5

Proposed high-risk screening protocol for Fabry disease in patients with renal and vascular disease.

Auray-Blais C, Millington DS, Young SP, Clarke JT, Schiffmann R. Auray-Blais C, et al. J Inherit Metab Dis. 2009 Apr;32(2):303-8. doi: 10.1007/s10545-009-1055-6. Epub 2009 Jan 26. J Inherit Metab Dis. 2009. PMID: 19169844

6

Fabry disease urinary globotriaosylceramide/creatinine biomarker evaluation by liquid chromatography-tandem mass spectrometry in healthy infants from birth to 6 months.

Barr C, Clarke JT, Ntwari A, Drouin R, Auray-Blais C. Barr C, et al. Mol Genet Metab. 2009 Aug;97(4):278-83. doi: 10.1016/j.ymgme.2009.04.009. Epub 2009 May 3. Mol Genet Metab. 2009. PMID: 19464216

7

How well does urinary lyso-Gb3 function as a biomarker in Fabry disease?

Auray-Blais C, Ntwari A, Clarke JT, Warnock DG, Oliveira JP, Young SP, Millington DS, Bichet DG, Sirrs S, West ML, Casey R, Hwu WL, Keutzer JM, Zhang XK, Gagnon R. Auray-Blais C, et al. Clin Chim Acta. 2010 Dec 14;411(23-24):1906-14. doi: 10.1016/j.cca.2010.07.038. Epub 2010 Aug 14. Clin Chim Acta. 2010. PMID: 20716442

8

Urinary globotriaosylsphingosine-related biomarkers for Fabry disease targeted by metabolomics.

Auray-Blais C, Boutin M, Gagnon R, Dupont FO, Lavoie P, Clarke JT. Auray-Blais C, et al. Anal Chem. 2012 Mar 20;84(6):2745-53. doi: 10.1021/ac203433e. Epub 2012 Feb 28. Anal Chem. 2012. PMID: 22309310

9

Novel gb(3) isoforms detected in urine of fabry disease patients: a metabolomic study.

Auray-Blais C, Boutin M. Auray-Blais C, et al. Curr Med Chem. 2012;19(19):3241-52. doi: 10.2174/092986712800784739. Curr Med Chem. 2012. PMID: 22612706

10

LC-MS/MS analysis of plasma lyso-Gb3 in Fabry disease.

Boutin M, Gagnon R, Lavoie P, Auray-Blais C. Boutin M, et al. Clin Chim Acta. 2012 Dec 24;414:273-80. doi: 10.1016/j.cca.2012.09.026. Epub 2012 Oct 2. Clin Chim Acta. 2012. PMID: 23041216

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

108 results

Search Page